Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
暂无分享,去创建一个
E. Antman | M. Sabatine | E. Braunwald | D. Morrow | S. Murphy | B. Scirica | B. Bergmark | S. Wiviott | M. Bonaca
[1] Samin K. Sharma,et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.
[2] M. Postma,et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. , 2019, The New England journal of medicine.
[3] W. Rottbauer,et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. , 2019, The New England journal of medicine.
[4] Á. Avezum,et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. , 2019, The New England journal of medicine.
[5] P. Serruys,et al. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. , 2019, European heart journal.
[6] H. Okayama,et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.
[7] Volkmar Falk,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.
[8] Jeroen J. Bax,et al. Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Circulation.
[9] D. Karalis,et al. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia. , 2018, The American journal of cardiology.
[10] Marco Valgimigli,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.
[11] Khalid Yusoff,et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2017, Lancet.
[12] P. Morange,et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study , 2017, European heart journal.
[13] M. Hadamitzky,et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial , 2017, The Lancet.
[14] Sunil V. Rao,et al. Bleeding and Mortality With Dual Antiplatelet Therapy: The Rashomon Effect. , 2017, Journal of the American College of Cardiology.
[15] Deepak L. Bhatt,et al. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. , 2017, Journal of the American College of Cardiology.
[16] Laura Mauri,et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.
[17] J. Massaro,et al. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. , 2016, Journal of the American College of Cardiology.
[18] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[19] J. Mega,et al. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial , 2015, European heart journal. Acute cardiovascular care.
[20] Walter Desmet,et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.
[21] Marc P. Bonaca,et al. Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.
[22] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[23] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[24] Antonio Colombo,et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.
[25] Marc P. Bonaca,et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. , 2014, American heart journal.
[26] M. Jeong,et al. Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial , 2014, Circulation.
[27] Deepak L. Bhatt,et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.
[28] Antonio Colombo,et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.
[29] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[30] Marc P. Bonaca,et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial , 2012, The Lancet.
[31] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .
[32] J. Marchesini,et al. Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.
[33] J. Hirsh,et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[34] M. Jeong,et al. Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.
[35] Paul Burton,et al. Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[36] Douglas Weaver,et al. Third universal definition of myocardial infarction. , 2012, Circulation.
[37] Hani Jneid,et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.
[38] Marc P. Bonaca,et al. ACC/AHA/ESC/WHF Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations from the TRITON-TIMI 38 Trial , 2011 .
[39] M. Pencina,et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent , 2010, American heart journal.
[40] M. Jeong,et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.
[41] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[42] E. Antman,et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. , 2008, Journal of the American College of Cardiology.
[43] Fred S Apple,et al. Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.
[44] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[45] Deepak L. Bhatt,et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.
[46] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[47] David B Matchar,et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.
[48] Patrick Hunziker,et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.
[49] E. Antman,et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.
[50] Harlan M. Krumholz,et al. Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry , 2006, Circulation.
[51] S. Yusuf,et al. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. , 2003, Journal of the American College of Cardiology.
[52] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[53] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.